Bristol Myers Company Profile

What is the competitive landscape for BRISTOL MYERS

BRISTOL MYERS has seventy-six approved drugs.

There are twelve US patents protecting BRISTOL MYERS drugs.

There are five hundred and ninety-seven patent family members on BRISTOL MYERS drugs in fifty-one countries and one hundred and forty-five supplementary protection certificates in eighteen countries.

Summary for Bristol Myers

International Patents:	597
US Patents:	12
Tradenames:	65
Ingredients:	58
NDAs:	76
Drug Master File Entries:	1

Drugs and US Patents for Bristol Myers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes	9,738,625			Y
Bristol Myers Squibb	REMSED	promethazine hydrochloride	TABLET;ORAL	083176-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	RUBRAMIN PC	cyanocobalamin	INJECTABLE;INJECTION	006799-010	Apr 28, 1988		DISCN	Yes	No
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-002	Jun 28, 2006	AB	RX	Yes	No	8,680,103*PED				Y
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-002	Jun 28, 2006	AB	RX	Yes	No
Bristol Myers Squibb	SUSTIVA	efavirenz	TABLET;ORAL	021360-002	Feb 1, 2002		DISCN	Yes	No
Bristol Myers Squibb	VITAMIN A	vitamin a palmitate	CAPSULE;ORAL	080860-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Bristol Myers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	CAPSULE;ORAL	021190-003	Dec 20, 2000	5,015,646*PED
Bristol Myers Squibb	PRAVIGARD PAC (COPACKAGED)	aspirin; pravastatin sodium	TABLET;ORAL	021387-005	Jun 24, 2003	5,622,985*PED
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	9,056,120
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	7,855,217
Bristol Myers Squibb	SERZONE	nefazodone hydrochloride	TABLET;ORAL	020152-001	Dec 22, 1994	4,338,317*PED
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-003	Jun 28, 2006	7,153,856*PED
Bristol Myers Squibb	ZERIT XR	stavudine	CAPSULE, EXTENDED RELEASE;ORAL	021453-003	Dec 31, 2002	7,135,465*PED

Paragraph IV (Patent) Challenges for BRISTOL MYERS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	50 mg, 100 mg and 200 mg		2016-11-03
	Tablets	0.5 mg and 1 mg		2010-06-14
	Tablets	30 mg		2005-06-01
	Tablets	80 mg and 140 mg		2011-06-16
	Capsules	25 mg		2010-07-12
	Capsules	2.5 mg and 20 mg		2016-07-12
	Capsules	100 mg and 150 mg		2010-03-19
	Tablets	600 mg		2009-04-09
	Nasal Spray	4 mg/spray		2016-07-15
	Tablets	2.5 mg and 5 mg		2016-12-28
	Tablets	20 mg, 50 mg, 70 mg and 100 mg		2010-06-28
	Tablets	80 mg and 140 mg		2011-06-17
	Delayed-release Capsules	200 mg, 250 mg and 400 mg		2004-06-01
	Capsules	5 mg, 10 mg and 15 mg		2010-08-30
	Capsules	300 mg		2009-07-20
	Capsules	200 mg		2010-02-16

International Patents for Bristol Myers Drugs

Country	Patent Number	Estimated Expiration
Israel	207458
Israel	178745
New Zealand	531616
Russian Federation	2007120710
Russian Federation	2008117432
South Korea	20090048520
Taiwan	I331526

Supplementary Protection Certificates for Bristol Myers Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1169038	2013/003	Ireland		PRODUCT NAME: DASATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120
1169038	6/2013	Austria		PRODUCT NAME: DASATINIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120
1427415	91888	Luxembourg		91888, EXPIRES: 20260518
0496835	C960031	Netherlands		PRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621
2782584	LUC00245	Luxembourg		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701
0481754	SPC/GB06/032	United Kingdom		PRODUCT NAME: ENTECAVIR-(2-AMINO-1,9-DIHYDRO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE CYCLOPENTYL)-6H-PURIN-6-ONE AND HYDRATES THEREOF, PARTICULARLY THE MONOHYDRATE; REGISTERED: UK EU/1/06/343/001 20060626; UK EU/1/06/343/002 20060626; UK EU/1/06/343/003 20060626; UK EU/1/06/343/004 20060626; UK EU/1/06/343/005 20060626
1304992	SPC/GB13/061	United Kingdom		PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers
• Bristol-myers Squibb

Bristol Myers Squibb: A Pharmaceutical Powerhouse in a Competitive Landscape

In the ever-evolving world of pharmaceuticals, Bristol Myers Squibb (BMS) stands as a formidable player, navigating complex market dynamics with strategic prowess. This analysis delves into BMS's market position, strengths, and strategic insights, offering a comprehensive view of the company's competitive landscape.

The BMS Advantage: A Diverse Portfolio

Bristol Myers Squibb's success stems from its diverse product portfolio, spanning multiple therapeutic areas. The company's focus on oncology, immunology, and cardiovascular diseases has positioned it as a leader in these high-growth sectors[1]. Key products like Opdivo, Eliquis, and Revlimid have been significant revenue drivers, showcasing BMS's ability to develop and market blockbuster drugs[6].

Research and Development: The Lifeblood of Innovation

At the heart of BMS's competitive edge lies its robust research and development (R&D) pipeline. The company's commitment to innovation is evident in its substantial R&D investments, which amounted to $4.8 billion in 2017, representing 23.1% of pharmaceutical sales[1]. This dedication to scientific advancement ensures a steady stream of potential breakthrough therapies.

"We want to accelerate our pipeline to deliver transformational medicines to patients around the globe. Pairing cutting-edge research and technology with our unmatched understanding of causal human biology, we aim to provide the best outcomes possible for patients today and in the future." - Robert Plenge, Executive Vice President, Chief Research Officer, Head of Research[5]

Global Footprint: Expanding Horizons

BMS's global presence is a key strength, allowing it to tap into diverse markets and patient populations. With operations spanning multiple countries, the company has established a robust international network that facilitates market penetration and revenue growth[3]. This global reach not only diversifies revenue streams but also provides valuable insights into regional healthcare needs and regulatory landscapes.

Strategic Partnerships: Fostering Collaboration

In the pharmaceutical industry, collaboration often breeds innovation. BMS has strategically positioned itself through partnerships and collaborations with academic institutions, biotech firms, and other industry players[6]. These alliances enhance the company's capabilities, accelerate innovation, and create opportunities for synergies in research and development.

Digital Transformation: Embracing the Future

In an era of rapid technological advancement, BMS is at the forefront of digital transformation in healthcare. The company is leveraging artificial intelligence, machine learning, and digital health technologies to enhance drug discovery, development, and patient care[5].

"The state of artificial intelligence and machine learning is similar to where we were with personal computers in 1980 — we are just getting started and there is so much more to discover. Technology and digital capabilities will transform our ways of working — from how we develop medicines, to how we improve the patient experience, to how we run our core business operations." - Greg Meyers, Executive Vice President, Chief Digital & Technology Officer[5]

Market Challenges: Navigating Patent Cliffs and Competition

Despite its strengths, BMS faces significant challenges. Patent expirations for key products like Revlimid pose a threat to future revenues[9]. Additionally, the company operates in a highly competitive landscape, with rivals like Pfizer, Merck, and Johnson & Johnson vying for market share[3]. Navigating these challenges requires strategic foresight and continuous innovation.

Financial Performance: A Snapshot of Success

BMS's financial performance reflects its strong market position. In 2023, the company reported total revenues of $45 billion, showcasing its ability to generate substantial sales despite market challenges[2]. This financial strength provides BMS with the resources to invest in R&D, pursue strategic acquisitions, and weather market fluctuations.

Corporate Responsibility: Beyond Profits

In today's business environment, corporate responsibility is increasingly important. BMS has been recognized for its efforts in this area, ranking 6th in the pharmaceutical and biotech industry on the JUST 100 rankings[7]. This recognition highlights the company's commitment to stakeholder value, ethical practices, and community impact.

Strategic Acquisitions: Expanding Capabilities

BMS has strategically used acquisitions to bolster its pipeline and expand its therapeutic reach. Recent acquisitions, such as Mirati Therapeutics and Karuna Therapeutics, demonstrate the company's commitment to strengthening its position in key therapeutic areas[4]. These strategic moves not only enhance BMS's product portfolio but also bring in new technologies and expertise.

Regulatory Environment: Navigating Complexities

The pharmaceutical industry is heavily regulated, and BMS must navigate a complex regulatory landscape. The company's ability to secure regulatory approvals for new drugs is crucial to its success. Recent approvals, such as that for Cobenfy in September 2024, showcase BMS's ability to bring novel treatments to market[4].

Emerging Markets: Tapping into New Opportunities

As developed markets become increasingly saturated, emerging markets present significant growth opportunities for BMS. The company's global presence positions it well to capitalize on these opportunities, but it must navigate unique challenges in these markets, including pricing pressures and regulatory differences[6].

Pricing Pressures: Balancing Access and Innovation

Like many pharmaceutical companies, BMS faces ongoing pressure to reduce drug prices. Balancing the need for affordable access to medicines with the high costs of drug development and innovation remains a significant challenge. The company's approach to this issue will be crucial in maintaining its market position and public perception.

Talent Acquisition and Retention: Fueling Innovation

In an industry driven by innovation, attracting and retaining top talent is crucial. BMS's reputation as a leading biopharmaceutical company helps in this regard, but the competition for skilled researchers, scientists, and executives remains fierce. The company's ability to foster a culture of innovation and provide meaningful career opportunities will be key to its continued success.

Future Outlook: Adapting to a Changing Landscape

As BMS looks to the future, several factors will shape its trajectory:

1. Pipeline Development: The success of drugs in late-stage clinical trials will be crucial for offsetting revenue losses from patent expirations.
2. Digital Integration: Continued investment in digital technologies and data analytics will be essential for maintaining a competitive edge.
3. Market Expansion: Penetration into emerging markets and new therapeutic areas will drive growth.
4. Regulatory Adaptation: Navigating evolving healthcare policies and regulations across global markets will be critical.
5. Sustainability Initiatives: Increasing focus on environmental, social, and governance (ESG) factors will influence corporate strategy and stakeholder perceptions.

Key Takeaways

• Bristol Myers Squibb maintains a strong market position through its diverse product portfolio and robust R&D pipeline.
• Strategic partnerships, digital transformation, and global presence are key strengths driving the company's competitive advantage.
• Challenges include patent expirations, intense competition, and pricing pressures.
• BMS's financial performance and strategic acquisitions demonstrate its ability to adapt and grow in a dynamic market.
• The company's future success will depend on pipeline development, digital integration, market expansion, regulatory adaptation, and sustainability initiatives.

FAQs

1. Q: What are Bristol Myers Squibb's main therapeutic areas of focus? A: BMS primarily focuses on oncology, immunology, and cardiovascular diseases, with key products in these areas driving significant revenue.

2. Q: How is BMS addressing the challenge of patent expirations? A: BMS is investing heavily in R&D, pursuing strategic acquisitions, and focusing on pipeline development to offset potential revenue losses from patent expirations.

3. Q: What role does digital technology play in BMS's strategy? A: Digital technology is crucial to BMS's future, with the company leveraging AI, machine learning, and digital health technologies to enhance drug discovery, development, and patient care.

4. Q: How does BMS's global presence contribute to its competitive advantage? A: BMS's global footprint allows it to tap into diverse markets, facilitating market penetration, revenue growth, and insights into regional healthcare needs.

5. Q: What sets BMS apart from its competitors in the pharmaceutical industry? A: BMS distinguishes itself through its strong R&D pipeline, strategic partnerships, digital transformation initiatives, and commitment to corporate responsibility.

Sources cited: [1] https://www.bms.com/about-us/our-impact/economic-responsibility/performance.html [2] https://www.fiercepharma.com/pharma/bristol-myers-ceo-outlines-transition-strategy-featuring-11-key-brands-continued-dealmaking [3] https://canvasbusinessmodel.com/blogs/competitors/bristol-myers-squibb-competitive-landscape [4] https://en.wikipedia.org/wiki/Bristol_Myers_Squibb [5] https://www.bms.com/about-us/our-company/our-technologies.html [6] https://pitchgrade.com/companies/bristol-myers-squibb [7] https://www.bms.com/life-and-science/news-and-perspectives/recognition-for-doing-right-by-their-stakeholders.html [9] https://www.investing.com/news/swot-analysis/bristolmyers-squibbs-swot-analysis-stock-outlook-mixed-amid-pipeline-progress-93CH-3848458